The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
|Articles|September 30, 2020
FDA Authorizes First Saline Oral Rinse Collection Test for COVID-19
Author(s)Kevin Kunzmann
The test provides qualitative detection of nucleic acid from SARS-CoV-2 in oral saline rinse specimens, nasopharyngeal swab, and nasal swab specimens in a universal transport media, as well as nasal swabs collected in oral saline rinse.
Advertisement
The US Food and Drug Administration (FDA) has amended the Emergency Use Authorization (EUA) for the OraRisk COVID-19 RT-PCR test, allowing for users of the device to be tested for
With the amended indication, the OralDNA Labs product becomes the first device with an EUA for a saline 30-second swish and gargle collection, eliminating need for nasal swab and saliva direct testing.
According to the company, the samples are viable for up to 72 hours, and no longer require cold pack transportation.
The test provides qualitative detection of nucleic acid from SARS-CoV-2 in oral saline rinse specimens, nasopharyngeal swab, and nasal swab specimens in a universal transport media, as well as nasal swabs collected in oral saline rinse. The test is designed for collection conducted by healthcare providers.
George Hoedeman, chief executive officer of OralDNA Labs, suggested oral rinse collection could be a “game-changer” in COVID-19 testing.
"A 30-second convenient collection without a nasal swab will improve patient comfort, minimize exposure risk to frontline healthcare professionals, shorten collection time, and avoid supply chain bottlenecks,” Hoedeman said. “These improvements, along with our exceptional turnaround times generally being shorter than our advertised 24-48 hours from sample receipt, will allow for an overall enhanced testing experience."
Advertisement
Related to this article
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
A 39-year-old unvaccinated Franklin County woman has died after a recent measles diagnosis. Nationally, numbers continue to increase and the US has passed 4,000 cases.
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4080 confirmed cases, 78% above all of 2025.
Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases
4
Early Antibiotic Stop in Neutropenic Fever Did Not Raise Severe Events
5